Venous Thromboembolism - Drug Pipeline Analysis and Market Forecasts to 2016
This report provides key data information and analysis on the VTE market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009 and forecasts forward seven years to 2016. The research also includes market characterization opportunities the unmet needs associated with VTE a competitive assessment product profiles of major marketed products and promising drugs in the pipeline an overview on discontinued projects implications for future market competition and the key players of the VTE market. ( http://www.bharatbook.com/detail.asp?id=132249&rt=Venous-Thromboembolism-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html )
The Venous Thromboembolism Therapeutics Market is Forecast to Show Moderate Growth Until 2016
This analysis suggests that the global venous thromboembolism (VTE) market was worth $1535m in 2009. It is forecast to grow at a compound annual growth rate (CAGR) of 6.5% for the next seven years to reach $2383m by 2016. This growth rate is primarily attributable to the strong current treatment options as well as strong pipeline candidates. This growth will be further supported by the high incidence rate of the disease increased uptake of factor Xa inhibitor and direct thrombin inhibitor and the launch of late-stage me-too candidates with improved efficacy and safety.
Venous Thromboembolism Market has Strong Competition between the Several Generics and Few Branded Products
The current competitive landscape for VTE drugs and found the competition to be strong. There are more than 10 marketed products for the treatment of VTE which includes anticoagulants and thrombolytics. Competition in the VTE market is driven not only by product characteristics such as their efficacy and safety profile but also by market characteristics such as the number of competitors pricing and generics. The VTE market is largely dominated by generic products (off-patent) which have a medium to high efficacy and safety profile. Although the current market has few branded products there is a strong competition between generics and branded products. The efficacy of the currently marketed product is high in terms of reducing total VTE events reducing proximal deep vein thrombosis (DVT) events and decreasing the risk of pulmonary embolism (PE). However the current marketed products are associated with some of the serious side effects such as increased risk of hemorrhage and thrombocytopenia. This implies that new targeted therapies with improved efficacy and safety profile are required. The competition in VTE market will further intensify with the launch of strong pipeline products which have improved efficacy and safety.
Venous Thromboembolism Market has Moderate Unmet Need
It has found that the global VTE market is a lucrative market with moderate levels of unmet need. The VTE market has a number of products with high efficacy and safety profiles. Although most marketed products have an acceptable efficacy and safety profile there lies an underlying opportunity to improve the therapeutic outcomes. Treatment options such as low-molecular-weight heparin (LMWH) vitamin K antagonists factor Xa inhibitors direct thrombin inhibitors and thrombolytics are effective in the management of VTE and the unmet need in term of efficacy is lower. However the safety profiles of marketed products are moderate and have some rare but serious side effects such as hemorrhage and thrombocytopenia. In summation the unmet need in the VTE market is moderate and can be fulfilled by products that target underserved patient populations and offer improved safety profile while being efficacious.
Opportunity and Unmet Need in the Venous Thromboembolism Market 2010 Source
Strong Clinical Pipeline has Several Me-too Molecules with Improved Efficacy and Safety Profile
The VTE pipeline found it to be strong. The VTE pipeline consists of more than 40 molecules currently in different stages of development. More than 70% of the VTE pipeline is accounted for by me-too molecules. In Phase III alone there are approximately 15 me-too molecules including some of the promising pipeline candidates. These products are expected to come up with better efficacy and safety profiles compared to the currently marketed products. Furthermore growth will be sustained by the development of oral anticoagulants which provide a rapid onset and offset of action and streamlined extended VTE therapy. A strong clinical pipeline coupled with moderate unmet needs in the VTE market is expected to help sustain the market’s growth rate during the forecast period.
To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=132249&rt=Venous-Thromboembolism-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Follow us on twitter: http://twitter.com/3bbharatbook